Literature DB >> 23901824

Mitophagy is required for acute cardioprotection by simvastatin.

Allen M Andres1, Genaro Hernandez, Pamela Lee, Chengqun Huang, Eric P Ratliff, Jon Sin, Christine A Thornton, Marichris V Damasco, Roberta A Gottlieb.   

Abstract

AIMS: We have shown that autophagy and mitophagy are required for preconditioning. While statin's cardioprotective effects are well known, the role of autophagy/mitophagy in statin-mediated cardioprotection is not. In this study, we used HL-1 cardiomyocytes and mice subjected to ischemia/reperfusion to elucidate the mechanism of statin-mediated cardioprotection.
RESULTS: HL-1 cardiomyocytes exposed to simvastatin for 24 h exhibited diminished protein kinase B (Akt)/mammalian target of rapamycin (mTOR) signaling, increased activation of unc-51-like kinase 1, and upregulation of autophagy and mitophagy. Similar findings were obtained in hearts of mice given simvastatin. Mevalonate abolished simvastatin's effects on Akt/mTOR signaling and autophagy induction in HL-1 cells, indicating that the effects are mediated through inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. Simvastatin-treated HL-1 cells exhibited mitochondrial translocation of Parkin and p62/SQSTM1, fission, and mitophagy. Because Parkin is required for mitophagy and is expressed in heart, we investigated the effect of simvastatin on infarct size in Parkin knockout mice. Simvastatin reduced infarct size in wild-type mice but showed no benefit in Parkin knockout mice. Inhibition of HMG-CoA reductase limits mevalonate availability for both cholesterol and coenzyme Q10 (CoQ) biosynthesis. CoQ supplementation had no effect on statin-induced Akt/mTOR dephosphorylation or macroautophagy in HL-1 cells, but it potently blocked mitophagy. Importantly, CoQ supplementation abolished statin-mediated cardioprotection in vivo. INNOVATION AND
CONCLUSION: Acute simvastatin treatment suppresses mTOR signaling and triggers Parkin-dependent mitophagy, the latter which is required for cardioprotection. Coadministration of CoQ with simvastatin impairs mitophagy and cardioprotection. These results raise the concern that CoQ may interfere with anti-ischemic benefits of statins mediated through stimulation of mitophagy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23901824      PMCID: PMC4208607          DOI: 10.1089/ars.2013.5416

Source DB:  PubMed          Journal:  Antioxid Redox Signal        ISSN: 1523-0864            Impact factor:   8.401


  59 in total

Review 1.  Upstream and downstream of mTOR.

Authors:  Nissim Hay; Nahum Sonenberg
Journal:  Genes Dev       Date:  2004-08-15       Impact factor: 11.361

Review 2.  The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes.

Authors:  Kausik K Ray; Christopher P Cannon
Journal:  J Am Coll Cardiol       Date:  2005-10-18       Impact factor: 24.094

3.  Acute administration of red yeast rice (Monascus purpureus) depletes tissue coenzyme Q(10) levels in ICR mice.

Authors:  Hui-Ting Yang; Shyh-Hsiang Lin; Shih-Yi Huang; Hsin-Ju Chou
Journal:  Br J Nutr       Date:  2005-01       Impact factor: 3.718

4.  Enhancing macroautophagy protects against ischemia/reperfusion injury in cardiac myocytes.

Authors:  Anne Hamacher-Brady; Nathan R Brady; Roberta A Gottlieb
Journal:  J Biol Chem       Date:  2006-08-01       Impact factor: 5.157

5.  Changes in PPAR gene expression and myocardial tolerance to ischaemia: relevance to pleiotropic effects of statins.

Authors:  Tána Ravingerová; Adriana Adameová; Tara Kelly; Efthymia Antonopoulou; Dezider Pancza; Mária Ondrejcáková; Vinoth Kumar Megraj Khandelwal; Slávka Carnická; Antigone Lazou
Journal:  Can J Physiol Pharmacol       Date:  2009-12       Impact factor: 2.273

6.  Amlodipine and atorvastatin exert protective and additive effects via antiapoptotic and antiautophagic mechanisms after transient middle cerebral artery occlusion in Zucker metabolic syndrome rats.

Authors:  Xuemei Zhang; Shoko Deguchi; Kentaro Deguchi; Yasuyuki Ohta; Toru Yamashita; Jingwei Shang; Fengfeng Tian; Ning Liu; Wentao Liu; Yoshio Ikeda; Tohru Matsuura; Koji Abe
Journal:  J Neurosci Res       Date:  2011-05-02       Impact factor: 4.164

7.  Hydrophobic statins induce autophagy and cell death in human rhabdomyosarcoma cells by depleting geranylgeranyl diphosphate.

Authors:  Makoto Araki; Masatomo Maeda; Kiyoto Motojima
Journal:  Eur J Pharmacol       Date:  2011-11-09       Impact factor: 4.432

8.  Autophagy activation: a novel mechanism of atorvastatin to protect mesenchymal stem cells from hypoxia and serum deprivation via AMP-activated protein kinase/mammalian target of rapamycin pathway.

Authors:  Qian Zhang; Yue-Jin Yang; Hong Wang; Qiu-Ting Dong; Tian-Jie Wang; Hai-Yan Qian; Hui Xu
Journal:  Stem Cells Dev       Date:  2012-03-28       Impact factor: 3.272

9.  Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stress-induced myocardial injury in adult mice.

Authors:  Chengqun Huang; Xiaoxue Zhang; Jennifer M Ramil; Shivaji Rikka; Lucy Kim; Youngil Lee; Natalie A Gude; Patricia A Thistlethwaite; Mark A Sussman; Roberta A Gottlieb; Asa B Gustafsson
Journal:  Circulation       Date:  2010-01-25       Impact factor: 29.690

Review 10.  Autophagy: an affair of the heart.

Authors:  Roberta A Gottlieb; Robert M Mentzer
Journal:  Heart Fail Rev       Date:  2013-09       Impact factor: 4.214

View more
  71 in total

1.  Autophagosome formation is required for cardioprotection by chloramphenicol.

Authors:  Zoltán Giricz; Zoltán V Varga; Gábor Koncsos; Csilla Terézia Nagy; Anikó Görbe; Robert M Mentzer; Roberta A Gottlieb; Péter Ferdinandy
Journal:  Life Sci       Date:  2017-08-01       Impact factor: 5.037

2.  Mitophagy protects against statin-mediated skeletal muscle toxicity.

Authors:  Mridula Ramesh; Juliane C Campos; Pamela Lee; Yang Song; Genaro Hernandez; Jon Sin; Kyle C Tucker; Hannaneh Saadaeijahromi; Michael Gurney; Julio C B Ferreira; Allen M Andres
Journal:  FASEB J       Date:  2019-08-23       Impact factor: 5.191

Review 3.  Mitochondrial reactive oxygen species at the heart of the matter: new therapeutic approaches for cardiovascular diseases.

Authors:  Opher S Kornfeld; Sunhee Hwang; Marie-Hélène Disatnik; Che-Hong Chen; Nir Qvit; Daria Mochly-Rosen
Journal:  Circ Res       Date:  2015-05-22       Impact factor: 17.367

Review 4.  Therapeutic targeting of autophagy: potential and concerns in treating cardiovascular disease.

Authors:  Amabel M Orogo; Åsa B Gustafsson
Journal:  Circ Res       Date:  2015-01-30       Impact factor: 17.367

Review 5.  Untangling autophagy measurements: all fluxed up.

Authors:  Roberta A Gottlieb; Allen M Andres; Jon Sin; David P J Taylor
Journal:  Circ Res       Date:  2015-01-30       Impact factor: 17.367

Review 6.  Mitophagy mechanisms and role in human diseases.

Authors:  Matthew Redmann; Matthew Dodson; Michaël Boyer-Guittaut; Victor Darley-Usmar; Jianhua Zhang
Journal:  Int J Biochem Cell Biol       Date:  2014-05-16       Impact factor: 5.085

7.  Phase I/IIa Trial of Atorvastatin in Patients with Acute Kawasaki Disease with Coronary Artery Aneurysm.

Authors:  Adriana H Tremoulet; Sonia Jain; Pei-Ni Jone; Brookie M Best; Elizabeth H Duxbury; Alessandra Franco; Beth Printz; Samuel R Dominguez; Heather Heizer; Marsha S Anderson; Mary P Glodé; Feng He; Robert L Padilla; Chisato Shimizu; Emelia Bainto; Joan Pancheri; Harvey J Cohen; John C Whitin; Jane C Burns
Journal:  J Pediatr       Date:  2019-09-24       Impact factor: 4.406

Review 8.  Mitochondria and cardiovascular diseases-from pathophysiology to treatment.

Authors:  Gerasimos Siasos; Vasiliki Tsigkou; Marinos Kosmopoulos; Dimosthenis Theodosiadis; Spyridon Simantiris; Nikoletta Maria Tagkou; Athina Tsimpiktsioglou; Panagiota K Stampouloglou; Evangelos Oikonomou; Konstantinos Mourouzis; Anastasios Philippou; Manolis Vavuranakis; Christodoulos Stefanadis; Dimitris Tousoulis; Athanasios G Papavassiliou
Journal:  Ann Transl Med       Date:  2018-06

9.  Chronic HMGCR/HMG-CoA reductase inhibitor treatment contributes to dysglycemia by upregulating hepatic gluconeogenesis through autophagy induction.

Authors:  Hye Jin Wang; Jae Yeo Park; Obin Kwon; Eun Yeong Choe; Chul Hoon Kim; Kyu Yeon Hur; Myung-Shik Lee; Mijin Yun; Bong Soo Cha; Young-Bum Kim; Hyangkyu Lee; Eun Seok Kang
Journal:  Autophagy       Date:  2015-11-02       Impact factor: 16.016

Review 10.  Engineering cardiac microphysiological systems to model pathological extracellular matrix remodeling.

Authors:  Nethika R Ariyasinghe; Davi M Lyra-Leite; Megan L McCain
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-06-15       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.